FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891095590> ?p ?o ?g. }

• W2891095590 endingPage "8541" @default.
• W2891095590 startingPage "8541" @default.
• W2891095590 abstract "8541 Background: Platinum-based chemotherapy, before or after surgery, provides only a 5% benefit in 5yr. OS in locally advanced NSCLC. A recent pilot study (JCO 2017 35:15suppl, 8508) showed that preoperative immune checkpoint inhibitor therapy was well tolerated and yielded a clinically meaningful major pathologic response rate (MPR ≤10% residual viable tumor cells). This large multicenter trial tests the MPR rate and novel biomarkers of benefit using this novel neoadjuvant approach with atezolizumab (atezo) [NCT02927301]. Methods: Pts with stages IB -selected IIIB resectable NSCLC were to receive 2 cycles of atezo (1200 mg, days 1, 22) then undergo resection (day 40 +/- 10). Chest CT, PET obtained pre- and post atezo to assess clinical response. Primary tumor +/- node biopsies and blood samples were obtained before atezo and at surgery for biomarker studies. The primary endpoint was MPR. Secondary endpoints included safety, response by PD-L1, OS, and DFS. Results: For the prespecified initial safety analysis, the first 21 of 180 planned pts (67 pts currently on study) are reported: 13 males, median age 65 y, all ECOG 0-1; 4 current, 16 former smokers; 13 non-squamous NSCLC; clinical stages Ib/IIa/IIb/IIIa/IIIb = 4/2/6/5/4. Two pts received one dose of atezo due to treatment related AE (Gr 1 pyrexia, Gr 2 dyspnea) but underwent uncomplicated resection with MPR assessment. There were no Gr 5 AE, 5 Gr 3-4 AE (1 treatment related). By RECIST, 20 pts had SD, and 1 had PD. There were no major delays to surgery. 19 pts had MPR assessment: 1 pt discontinued atezo preop due to CNS mets and 1 pt had unresectable disease. MPR rate was 4/19 (21%, 95% CI 6-46). Excluding 2 pts who had known driver mutations (1 EGFR+, 1 ALK+), MPR rate was 4/17 (24%, 95% CI 7-50). 11/19 patients had ≤50% viable tumor. Conclusions: This first report of atezo in the neoadjuvant setting shows that preoperative treatment is feasible and well tolerated. MPR rate is encouraging. Clinical and pathological responses are often discordant. Safety and efficacy results from additional pts will be presented. Correlative analyses on pre- and post atezo tissues are ongoing. Preliminary correlative analyses in blood samples are included in a separate abstract. Clinical trial information: NCT02927301." @default.
• W2891095590 created "2018-09-27" @default.
• W2891095590 creator A5000609254 @default.
• W2891095590 creator A5002656601 @default.
• W2891095590 creator A5004054300 @default.
• W2891095590 creator A5010278316 @default.
• W2891095590 creator A5021339490 @default.
• W2891095590 creator A5028085268 @default.
• W2891095590 creator A5034467403 @default.
• W2891095590 creator A5034705456 @default.
• W2891095590 creator A5039000673 @default.
• W2891095590 creator A5039791495 @default.
• W2891095590 creator A5044266059 @default.
• W2891095590 creator A5051283101 @default.
• W2891095590 creator A5053521833 @default.
• W2891095590 creator A5055597008 @default.
• W2891095590 creator A5059652753 @default.
• W2891095590 creator A5060287300 @default.
• W2891095590 creator A5064494204 @default.
• W2891095590 creator A5071670695 @default.
• W2891095590 creator A5080011474 @default.
• W2891095590 creator A5090385143 @default.
• W2891095590 date "2018-05-20" @default.
• W2891095590 modified "2023-10-10" @default.
• W2891095590 title "Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3)." @default.
• W2891095590 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.8541" @default.
• W2891095590 hasPublicationYear "2018" @default.
• W2891095590 type Work @default.
• W2891095590 sameAs 2891095590 @default.
• W2891095590 citedByCount "38" @default.
• W2891095590 countsByYear W28910955902018 @default.
• W2891095590 countsByYear W28910955902019 @default.
• W2891095590 countsByYear W28910955902020 @default.
• W2891095590 countsByYear W28910955902021 @default.
• W2891095590 countsByYear W28910955902022 @default.
• W2891095590 countsByYear W28910955902023 @default.
• W2891095590 crossrefType "journal-article" @default.
• W2891095590 hasAuthorship W2891095590A5000609254 @default.
• W2891095590 hasAuthorship W2891095590A5002656601 @default.
• W2891095590 hasAuthorship W2891095590A5004054300 @default.
• W2891095590 hasAuthorship W2891095590A5010278316 @default.
• W2891095590 hasAuthorship W2891095590A5021339490 @default.
• W2891095590 hasAuthorship W2891095590A5028085268 @default.
• W2891095590 hasAuthorship W2891095590A5034467403 @default.
• W2891095590 hasAuthorship W2891095590A5034705456 @default.
• W2891095590 hasAuthorship W2891095590A5039000673 @default.
• W2891095590 hasAuthorship W2891095590A5039791495 @default.
• W2891095590 hasAuthorship W2891095590A5044266059 @default.
• W2891095590 hasAuthorship W2891095590A5051283101 @default.
• W2891095590 hasAuthorship W2891095590A5053521833 @default.
• W2891095590 hasAuthorship W2891095590A5055597008 @default.
• W2891095590 hasAuthorship W2891095590A5059652753 @default.
• W2891095590 hasAuthorship W2891095590A5060287300 @default.
• W2891095590 hasAuthorship W2891095590A5064494204 @default.
• W2891095590 hasAuthorship W2891095590A5071670695 @default.
• W2891095590 hasAuthorship W2891095590A5080011474 @default.
• W2891095590 hasAuthorship W2891095590A5090385143 @default.
• W2891095590 hasConcept C121608353 @default.
• W2891095590 hasConcept C126322002 @default.
• W2891095590 hasConcept C126894567 @default.
• W2891095590 hasConcept C143998085 @default.
• W2891095590 hasConcept C203092338 @default.
• W2891095590 hasConcept C2775949291 @default.
• W2891095590 hasConcept C2776256026 @default.
• W2891095590 hasConcept C2776694085 @default.
• W2891095590 hasConcept C2777701055 @default.
• W2891095590 hasConcept C2778292576 @default.
• W2891095590 hasConcept C2779177807 @default.
• W2891095590 hasConcept C2780030458 @default.
• W2891095590 hasConcept C530470458 @default.
• W2891095590 hasConcept C535046627 @default.
• W2891095590 hasConcept C71924100 @default.
• W2891095590 hasConcept C81729549 @default.
• W2891095590 hasConceptScore W2891095590C121608353 @default.
• W2891095590 hasConceptScore W2891095590C126322002 @default.
• W2891095590 hasConceptScore W2891095590C126894567 @default.
• W2891095590 hasConceptScore W2891095590C143998085 @default.
• W2891095590 hasConceptScore W2891095590C203092338 @default.
• W2891095590 hasConceptScore W2891095590C2775949291 @default.
• W2891095590 hasConceptScore W2891095590C2776256026 @default.
• W2891095590 hasConceptScore W2891095590C2776694085 @default.
• W2891095590 hasConceptScore W2891095590C2777701055 @default.
• W2891095590 hasConceptScore W2891095590C2778292576 @default.
• W2891095590 hasConceptScore W2891095590C2779177807 @default.
• W2891095590 hasConceptScore W2891095590C2780030458 @default.
• W2891095590 hasConceptScore W2891095590C530470458 @default.
• W2891095590 hasConceptScore W2891095590C535046627 @default.
• W2891095590 hasConceptScore W2891095590C71924100 @default.
• W2891095590 hasConceptScore W2891095590C81729549 @default.
• W2891095590 hasIssue "15_suppl" @default.
• W2891095590 hasLocation W28910955901 @default.
• W2891095590 hasOpenAccess W2891095590 @default.
• W2891095590 hasPrimaryLocation W28910955901 @default.
• W2891095590 hasRelatedWork W2055244776 @default.
• W2891095590 hasRelatedWork W2348529436 @default.
• W2891095590 hasRelatedWork W2413020017 @default.
• W2891095590 hasRelatedWork W2569676502 @default.
• W2891095590 hasRelatedWork W2767403930 @default.

• next